Development of Antidiabetic Nanomedicine from Stevioside

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2011 English Publisher:American Scientific PublishersJournal:Journal of Biomedical Nanotechnology, volume 7, pages 54-55 (issn: 1550-7033,

Copyright policy )

Authors: Subhash C, Yadav; Sudesh K, Yadav; Anil, Sood; Mohit, Sharma; Bikram, Singh;

doi: 10.1166/jbn.2011.1198

pmid: 21485800

Development of Antidiabetic Nanomedicine from Stevioside

- Summary
- Subjects
- Metrics

Abstract

Stevioside, a non-caloric sweetener has huge therapeutic potential as an antidiabetic biomolecule. Stevioside nano-bioconjugated on PEG-PLA nanoparticles of size 150-170 nm showed the initial burst phase followed by the slow controlled release of 2 h and 21 days respectively.

Related Organizations

Keywords

Diffusion, Glucosides, Nanocapsules, Drug Compounding, Hypoglycemic Agents, Particle Size, Diterpenes, Kaurane

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	4
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average